Otto ME

Centre for Human Drug Research, Leiden, the Netherlands.

7 papers · ORCID

ArticleDMT

Safety, pharmacokinetics, and pharmacodynamics of intravenously administered deuterated N,N-dimethyltryptamine (CYB004) in healthy volunteers.

van der Heijden KV, Jacobs GE, James EH +6

Europe PMC2026

ArticleDMT

Pharmacokinetics, pharmacodynamics and safety of N,N-dimethyltryptamine administered intravenously in healthy smoking and non-smoking volunteers.

van der Heijden KV, Makai-Bölöni S, Inamdar A +9

Europe PMC2026

ArticlePsilocybin

A novel psychedelic 5-HT2A receptor agonist GM-2505: The pharmacokinetic, safety, and pharmacodynamic profile from a randomized trial healthy volunteer.

Marek GJ, Makai-Bölöni S, Umbricht D +16

Europe PMC2026

ArticleDMT

Safety, Pharmacokinetics, and Pharmacodynamics of a 6-h N,N-Dimethyltryptamine (DMT) Infusion in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled Trial.

van der Heijden KV, Zuiker RGJA, Otto ME +7

Europe PMC2025

ArticlePsilocybin

Correction: Clinical Pharmacokinetics of Psilocin After Psilocybin Administration: A Systematic Review and Post‑Hoc Analysis.

Otto ME, van der Heijden KV, Schoones JW +4

Europe PMC2025

ArticleDMT

Clinical Pharmacokinetics of N,N-Dimethyltryptamine (DMT): A Systematic Review and Post-hoc Analysis.

van der Heijden KV, Otto ME, Schoones JW +5

Europe PMC2025

ArticlePsilocybin

Clinical Pharmacokinetics of Psilocin After Psilocybin Administration: A Systematic Review and Post-Hoc Analysis.

Otto ME, van der Heijden KV, Schoones JW +4

Europe PMC2025

Otto ME

Safety, pharmacokinetics, and pharmacodynamics of intravenously administered deuterated <i>N,N</i>-dimethyltryptamine (CYB004) in healthy volunteers.

Pharmacokinetics, pharmacodynamics and safety of <i>N,N</i>-dimethyltryptamine administered intravenously in healthy smoking and non-smoking volunteers.

A novel psychedelic 5-HT<sub>2A</sub> receptor agonist GM-2505: The pharmacokinetic, safety, and pharmacodynamic profile from a randomized trial healthy volunteer.

Safety, Pharmacokinetics, and Pharmacodynamics of a 6-h N,N-Dimethyltryptamine (DMT) Infusion in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled Trial.

Correction: Clinical Pharmacokinetics of Psilocin After Psilocybin Administration: A Systematic Review and Post‑Hoc Analysis.

Clinical Pharmacokinetics of N,N-Dimethyltryptamine (DMT): A Systematic Review and Post-hoc Analysis.

Clinical Pharmacokinetics of Psilocin After Psilocybin Administration: A Systematic Review and Post-Hoc Analysis.

Otto ME

Safety, pharmacokinetics, and pharmacodynamics of intravenously administered deuterated &lt;i&gt;N,N&lt;/i&gt;-dimethyltryptamine (CYB004) in healthy volunteers.

Pharmacokinetics, pharmacodynamics and safety of &lt;i&gt;N,N&lt;/i&gt;-dimethyltryptamine administered intravenously in healthy smoking and non-smoking volunteers.

A novel psychedelic 5-HT&lt;sub&gt;2A&lt;/sub&gt; receptor agonist GM-2505: The pharmacokinetic, safety, and pharmacodynamic profile from a randomized trial healthy volunteer.

Safety, Pharmacokinetics, and Pharmacodynamics of a 6-h N,N-Dimethyltryptamine (DMT) Infusion in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled Trial.

Correction: Clinical Pharmacokinetics of Psilocin After Psilocybin Administration: A Systematic Review and Post‑Hoc Analysis.

Clinical Pharmacokinetics of N,N-Dimethyltryptamine (DMT): A Systematic Review and Post-hoc Analysis.

Clinical Pharmacokinetics of Psilocin After Psilocybin Administration: A Systematic Review and Post-Hoc Analysis.

Safety, pharmacokinetics, and pharmacodynamics of intravenously administered deuterated <i>N,N</i>-dimethyltryptamine (CYB004) in healthy volunteers.

Pharmacokinetics, pharmacodynamics and safety of <i>N,N</i>-dimethyltryptamine administered intravenously in healthy smoking and non-smoking volunteers.

A novel psychedelic 5-HT<sub>2A</sub> receptor agonist GM-2505: The pharmacokinetic, safety, and pharmacodynamic profile from a randomized trial healthy volunteer.